Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
formoterol + tiotropium
- Development stage
- Unknown
- Lead developer
- Midas Care
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Duo-Tiovent is a fixed-dose combination inhalation therapy developed by Midas Care for the management of obstructive airway diseases. It contains formoterol, a long-acting beta2-adrenergic agonist (LABA), and tiotropium, a long-acting muscarinic antagonist (LAMA). Formoterol acts by stimulating beta2-receptors in the lungs, leading to rapid and sustained bronchodilation by relaxing airway smooth muscle. Tiotropium works by blocking M3 muscarinic receptors, which inhibits the bronchoconstrictive effects of acetylcholine. This dual mechanism provides synergistic effects, improving lung function and reducing symptoms more effectively than either agent alone. It is primarily indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
- Brand names
- Duo-TioventDuo-Tiovent-Midas Care-small molecule-combination product-inhalation
- Other names
- formoterol fumarate + tiotropium bromidetiotropium + formoterolDuo-Tiovent-Midas Care-small molecule-combination product-inhalation
02
Targets
CHRM4 (M4)CHRM3 (M3)ADRB2 (β2)M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)ADRB3 (β3)CHRM5 (M5)ADRB1 (β1)
Beyond the preview
Go deeper on formoterol + tiotropium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on formoterol + tiotropium.